Global Drug Discovery Market Research Report
- Report Code: DR 1000
- Publish Date: Upcoming
Drug Discovery and its peer markets - Genetic Engineering, Transcriptomics, Biomarkers, Genomics, Metabolomics, Bio-MEMS, Drug Development, Microfluidics, Toxicology and 4 other markets - adds up to total Life Sciences Research market.
Drug Discovery can be segmented by Submarkets, Technologies and Types. Submarkets of this market are Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research and Next Generation Sequencing (NGS). Technologies of this market are NGS Platforms/Consumables/Services and Genomics. Types of this market are In vitro drug discovery and In vivo drug discovery.
Drug Discovery can be segmented by Submarkets, Technologies and Types. Submarkets of this market are Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research and Next Generation Sequencing (NGS). Technologies of this market are NGS Platforms/Consumables/Services and Genomics. Types of this market are In vitro drug discovery and In vivo drug discovery.
Key Questions Answered
- What are market estimates and forecasts; which of Drug Discovery markets are doing well and which are not?
- This reports provides most granular segmentation on Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation and RNA Interference.
- This report provides market sizing and forecast for the Drug Discovery market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
- Global Drug Discovery companies
- Manufacturing Companies
- Traders, distributors, and suppliers
- Governmental and research organizations
- Associations and industry bodies
- Technology providers
What makes our report unique?
Audience for this report
1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
2 Executive Summary
3 Market Overview
4 By Submarkets
4.1 Next Generation Sequencer (NGS)
4.2 Metabolomics
4.3 Biobanking/Biopreservation
4.4 RNA Interference
4.5 Biomarkers
4.6 Stem cell research
4.7 Next Generation Sequencing (NGS)
5 By Technologies
5.1 NGS Platforms/Consumables/Services
5.2 Genomics
6 By Types
6.1 In vitro drug discovery
6.2 In vivo drug discovery
Please fill in the form below to receive a free copy of the Summary of this Report
Custom Market Research Services
We will customize the research for you, in case the report listed above does not
meet with your exact requirements. Our custom research will comprehensively cover
the business information you require to help you arrive at strategic and profitable
business decisions.
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
Cell based assays Cell based assays and Next Generation Sequencer (NGS), Metabolomics, |
Upcoming |
|
|
Payment Link- High throughput screening The global High Throughput Screening market was valued at $14.38 billion in 2013 and is expected to reach $20.58 billion by 2018, growing at a CAGR of 7.4% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
Mice Model & Services Mice Model & Services and Next Generation Sequencer (NGS), Metabolomics, |
Upcoming |
|
|
High content analysis/Screening The global High Content Screening market was valued at $380.31 million in 2013 and is expected to reach $646.59 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments, consumables, software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), among others |
Upcoming |
|
|
Cages Cages and Bedding and Feed adds up to total |
Upcoming |
|
|
Bedding Bedding and Cages and Feed adds up to total |
Upcoming |
|
|
Feed Feed and Cages and Bedding adds up to total |
Upcoming |
|
|
Pending Secure Payment Link - Axenis Mice Model and Mice Model Services adds up to total Mice Model... |
Upcoming |
|
|
Mice Model Services Mice Model Services and Mice Model adds up to total Mice Model &... |
Upcoming |
|
|
North American High Content analysis/Screening The North American High Content Screening market was valued at $161.8 million in 2013 and is expected to reach $280.7 million by 2018, growing at a CAGR of 11.7% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
European High content analysis/Screening The European High Content Screening market was valued at $124.29 million in 2013 and is expected to reach $207.9 million by 2018, growing at a CAGR of 10.6% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
Asian High content analysis/Screening The Asian High Content Screening market was valued at $55.75 million in 2013 and is expected to reach $101.74 million by 2018, growing at a CAGR of 12.8% from 2013 to 2018.High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
North American High throughput screening The North American High Throughput Screening market was valued at $6454.3 million in 2013 and is expected to reach $9046.8 million by 2018, growing at a CAGR of 7.0% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
European High throughput screening The European High Throughput Screening market was valued at $3794.7 million in 2013 and is expected to reach $5194.3 million by 2018, growing at a CAGR of 6.5% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
|
|
Asian High throughput screening The Asian High Throughput Screening market was valued at $2547.3 million in 2013 and is expected to reach $3931.2 million by 2018, growing at a CAGR of 9.1% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland). |
Upcoming |
15 reports |
Show
Drug Discovery
